Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis

  1. Matías J. Pereson
  2. Lucas Amaya
  3. Karin Neukam
  4. Patricia Baré
  5. Natalia Echegoyen
  6. María Noel Badano
  7. Alicia Lucero
  8. Antonella Martelli
  9. Gabriel H. Garcia
  10. Cristina Videla
  11. Alfredo P. Martínez
  12. Federico A. Di Lello

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.cmi.2022.05.009
  2. ScreenIT

    SciScore for 10.1101/2022.04.08.22273532: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Ethical aspects: The study was designed and performed according to the Helsinki declaration and all blood donors gave their written informed consent (Study protocol EX-2021-06438339--UBA-DME#SSA_FFYB, Ethics committee of the Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires).
    IRB: Ethical aspects: The study was designed and performed according to the Helsinki declaration and all blood donors gave their written informed consent (Study protocol EX-2021-06438339--UBA-DME#SSA_FFYB, Ethics committee of the Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA).
    Anti-S-RBD
    suggested: None
    Software and Algorithms
    SentencesResources
    Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA).
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    Statistical analyses were carried out using the SPSS statistical software package release 23.0 (IBM SPSS Inc., Chicago, IL, USA).
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This study has some limitations. First, due to the observational, real-world design of our study, the vaccination scheme distribution was not randomized and depended on the risk priorities established by the Ministry of Health. Due to the limited availability of doses, the SpV/SpV group was mostly formed by active healthcare-workers who were at highest priority for vaccination at the time and benefited from the last available Sputnik V boost doses. In contrast, the SpV/Mod scheme was mostly applied to individuals older than 60 years old who were at intermediate priority. Apart from age distribution, the limited supply of the second component of Sputnik V led to almost 4-fold differences in the median interval between prime and boost immunization, since the Moderna vaccine was also not immediately available once the shortage of Sputnik V was evident. However, there was no correlation between age or the time intervals used in this study and the anti-S-RBD levels. As a result, when the samples were stratified according to age, ΔP-B, and ΔB-antiSRBD, no significant differences of the antibody titers were observed between different levels of categorization within each vaccine scheme group, while the significant difference in anti-S-RBD between the two vaccine scheme groups was maintained. Therefore, both populations can be regarded as comparable and an impact of differences in age and time intervals on the analyses is very unlikely in the present setting. Second, due to the lack o...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.04.08.22273532v1 on medRxiv